Chicago—Preliminary results have demonstrated that three-component prothrombin complex concentrates (PCCs) reduce total blood products transfused for excessive bleeding in cardiac surgery patients. However, this benefit may come at the cost of increased thrombotic complications.
“Although the FDA has approved prothrombin complex concentrates for Coumadin [warfarin, Bristol-Myers Squibb] reversal and hemophilia, the use of PCCs in these populations is not FDA approved,” said